Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Connecticut for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Connecticut only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Connecticut (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Pouyan Changizzadeh (NPI 1982047981)

Field	Value
Entity Type	Individual
Organization	Pouyan Changizzadeh
Address	1244 Storrs Rd
City	Storrs
State	CT
ZIP	06268
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 10, 2013

Payer Source	Total Paid
Medicare	$1.1M
Medicaid	$0

Key Findings

POUYAN CHANGIZZADEH’s Medicare billing is concentrated in oncology drug administration: the single largest revenue source is J9271 (pembrolizumab) with $473K representing 47.5% of the provider’s total Medicare revenue, and the top three Medicare codes account for 72.3% of total Medicare revenue. This mix indicates the practice is primarily delivering high-volume infused immunotherapy and bone-modifying agents rather than a broad primary care panel of services, consistent with the Hematology & Oncology taxonomy.

Medicaid billing is absent for this provider — the record shows no Medicaid billing on file. As a result, the provider is effectively a single-payer (Medicare) earner in the available claims data, which concentrates revenue exposure to Medicare reimbursement policy and beneficiary mix.

Denosumab (J0897) and pembrolizumab (J9271) together represent a dominant portion of the revenue stream beyond the single largest code: J0897 produced $192.2K (19.3% of Medicare revenue) and, with J9271, reflects a business model centered on in-office administration of specialty injectables and biologics. That drug-heavy revenue footprint suggests clinical throughput and infusion capacity are central to the provider’s operations rather than high-volume routine office evaluation and management alone.

Routine E/M and care coordination codes are present but secondary: 99214 and 99215 together account for measurable ambulatory evaluation revenue ($50.1K and $40K respectively) and 99490 contributes $54K for chronic care management, indicating that while the practice administers complex therapies, it also bills for moderate- to high-complexity outpatient visits and provider-directed care coordination. This pattern is consistent with oncology follow-up and chronic disease management accompanying infusion services.

Competitive standing on key codes is mixed. For pembrolizumab (J9271) the provider ranks #1054 of 1841 (42nd percentile), indicating typical, unremarkable national volume for that immunotherapy; by contrast J0897 ranks at the 90th percentile nationally (#1027 of 10057), signaling comparatively strong use of denosumab versus peers. Several office visit and lab codes (e.g., 99215 at the 96th percentile, 85025 at the 95th percentile, and 36415 at the 98th percentile) show above-typical national activity for those services, suggesting the provider is more active than most peers in these operational areas despite not being a national leader on the flagship oncology drug.

Tenure on file is substantial: the NPI was enumerated on 2013-04-10 (~13 years ago). This length of enumeration supports that the observed drug-administration and E/M billing patterns represent an established practice rather than a short-term reporting artifact.

There are notable statistical descriptors in the dataset that help interpret relative activity: 99215 is labeled notably above typical national volume (96th percentile), indicating higher-than-typical billing for high-complexity outpatient visits, while most chemotherapy administration and infusion codes are described as typical or unremarkable in volume. These characterizations suggest the provider delivers a higher-than-usual share of complex clinic visits alongside routine infusion volumes.

Laboratory and procedure volumes appear substantial for a specialty practice: codes such as 85025 (CBC), 36415 (venipuncture), and 80053 (CMP) are all in the high national percentiles (95th–98th) and together contribute multiple small revenue lines. This supports an in-house workflow where lab draws and panel testing accompany infusion and oncology visits rather than reliance on external lab vendors.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

63 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	11,000	$40	$473K
J0897	Injection, denosumab, 1 mg	10,680	$20	$192.2K
99490	The clinical staff provides services directed by the provider to support and coordinate a patient’s care across multiple disciplines. The patient has two or more chronic conditions that place the…	1,040	$50	$54K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	500	$100	$50.1K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	290	$140	$40K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	250	$120	$28.5K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	170	$130	$22.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	250	$70	$16.8K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	1,940	$10	$11.7K
85025	A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a…	1,400	$10	$11.2K

Showing 1–10 of 63

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 63 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Connecticut Distribution

Pouyan Changizzadeh — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Connecticut

Full comparison — all codes billed, vs. state median

63 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	10	9,000	$40	$414.6K
99439	57	70	80	$40	$241.1K
99490	8	170	180	$60	$157.4K
J3490	19	20	50	$1,380	$76K
J0897	4	100	2,700	$20	$66.4K
J0885	4	10	2,710	$10	$25.7K
J9217	10	30	150	$130	$20.2K
J0881	5	10	6,550	$1	$14.5K
99214	368	6,480	90	$90	$14.2K
96413	5	50	110	$110	$13.6K

Showing 1–10 of 63

Related Providers

Other providers that share a Tax Identification Number (TIN) with Pouyan Changizzadeh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Hartford Hospital	CT	General Acute Care Hospital	$0	$316.3M
Hartford Healthcare Medical Group Specialists, PLLC	CT	Surgery Physician	$0	$46M
Hartford Hospital	CT	Surgery Physician	$0	$27.5M
Hartford Healthcare Medical Group, Inc	CT	Surgery Physician	$0	$22.4M
Eastern Connecticut Hematology & Oncology Associates PC	CT	Hematology & Oncology Physician	$0	$2M
Philip Simkovitz	CT	Critical Care Medicine (Internal Medicine) Physician	$589.2K	$506K
Nikia Bray	CT	Family Nurse Practitioner	$58.9K	$557K
Dinesh Kapur	CT	Hematology & Oncology Physician	$494.8K	$0
Rabindranath Mahabir	CT	Internal Medicine Physician	$166.9K	$299.3K
Duarte Machado	CT	Neurology Physician	$390.7K	$0

Nearby Providers

Other providers in the same ZIP code as Pouyan Changizzadeh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Michele Cooper	CT	Medical Physician Assistant	$22.8K	$0

Pouyan Changizzadeh — Billing Profile & Reimbursement Data

Sign up for Pouyan Changizzadeh — Billing Profile & Reimbursement Data policy alerts

Pouyan Changizzadeh — Billing Profile & Reimbursement Data

Sign up for Pouyan Changizzadeh — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References